New study aims to map relapse and life quality in rare gynecologic cancers
NCT ID NCT07179757
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will follow 200 patients with vulvovaginal cancer who received radiation therapy (with or without chemotherapy) to see how the disease returns and how their quality of life changes over time. Researchers will also look at certain biological markers. The goal is to gather better data on these rare cancers to guide future research and treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this registry could identify key areas for future clinical trials and improve understanding of treatment outcomes in vulvovaginal cancers.
- What could go wrong
- This is an observational study, not a treatment trial. It cannot directly improve patient outcomes, and results may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2021
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will include patients who have completed radiation treatment for vulvo-vaginal cancer, and who are undergoing radiation treatment for vulvo-vaginal cancer.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. All patients diagnosed with vulvo- vaginal cancer. 2. Patients treated with Radiation+/- chemotherapy+/-surgery from January 1, 2019- December 31, 2023. Exclusion Criteria: 1. Patients with Metastatic disease at the presentation. 2. Incomplete information on the EMR.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Vaginal cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Tata Memorial Hospital
RECRUITINGMumbai, Maharashtra, 400012, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaginal scanner map tumors and cut MRI reliance?
- New drug combo targets HPV-Driven cancers in phase II trial
- New study aims to uncover why some women have worse sexual side effects from radiation
- Question list may empower gynecologic cancer patients in clinic
- Can a custom exercise plan boost survival in older women with gynecologic cancers?
- Embarrassment may be costing lives: study probes why women delay cancer checks